WITHDRAWN: Targeting of vitamin D supplementation to individuals with deficiency [0.03%]
已被撤销：针对维生素D缺乏个体的维生素D补充目标定位
Guillaume Butler-Laporte,J Brent Richards
Guillaume Butler-Laporte
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses [0.03%]
维生素D与冠心病、中风和全因死亡率风险关系的剂量反应评估：观察分析与孟德尔随机化分析
Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration
Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration
Background: Randomised trials of vitamin D supplementation for cardiovascular disease and all-cause mortality have generally reported null findings. However, generalisability of results to individuals with low vitamin D s...
Observational Study
The lancet. Diabetes & endocrinology. 2021 Dec;9(12):837-846. DOI:10.1016/S2213-8587(21)00263-1 2021
Josep M Mercader,Maggie C Y Ng,Alisa K Manning et al.
Josep M Mercader et al.
Ian R Reid
Ian R Reid
Consensus on diagnosis and management of Cushing's disease: a guideline update [0.03%]
库欣病的诊断和管理共识：指南更新
Maria Fleseriu,Richard Auchus,Irina Bancos et al.
Maria Fleseriu et al.
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. The Pituitary Society convened a consensus workshop comprising more than 50 academic researchers and clinical...
Newer antidiabetic agents: at what price will they be cost effective? [0.03%]
新型抗糖尿病药物：它们成为具成本效益的药价应是多少？
Ranjit Unnikrishnan,Viswanathan Mohan
Ranjit Unnikrishnan
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis [0.03%]
为低收入和中等收入国家的二型糖尿病患者扩大使用新药的机会：一项成本效益与定价目标分析
Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
Background: For patients with type 2 diabetes in low-income and middle-income countries (LMICs), access to newer antidiabetic drugs (eg, sodium-glucose co-transporter-2 [SGLT2] inhibitors, glucagon-like peptide-1 [GLP-1] ...
Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study [0.03%]
KDM1A在依赖GIP的主要双侧肾上腺大结节性增生合并库欣综合征中的丢失：一项多中心、回顾性队列研究
Fanny Chasseloup,Isabelle Bourdeau,Antoine Tabarin et al.
Fanny Chasseloup et al.
Background: GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome is caused by aberrant expression of the GIP receptor in adrenal lesions. The bilateral nature of this disease suggests g...
Ashley Grossman
Ashley Grossman
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology